GlobalData upgrades Pfizer’s COVID-19 vaccine sales forecast to $37 bn in 2022
In 2023, Comirnaty is expected to have an even better year, with sales forecasts up by 16 per cent
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
COMIRNATY
Moderna COVID-19 vaccine Spikevax sales to reduce amid strong competition: GlobalData
GlobalData expects Spikevax vaccine market share to decline from 30 per cent in 2022 to just 16 per cent by the end of 2028
Pfizer and BioNTech’s COVID-19 vaccine Comirnaty tops the list of best-selling drugs
Ends the nine-year reign of AbbVie’s Humira as the world’s best-selling pharma product
NIH launches trial to study allergic reactions to COVID-19 mRNA vaccine
The trial is seeking participants who experienced a mild or moderate systemic allergic reaction following the first dose of either…
Pfizer/BioNTech say data show COVID-19 vaccine safe and protective in kids
The companies said the vaccine generated an immune response in the five-to-11 year olds in their phase-II/III clinical trial that…
Pfizer/BioNTech’s vaccine to touch sales of $24.8 billion by 2021: GlobalData
Pfizer/BioNTech’s Comirnaty (tozinameran) is forecast to have peak sales of $24.8bn by 2021, which is only its second year on the…
Pfizer, BioNTech to Supply the EU with 100 mn additional COVID-19 vaccine doses
Total doses ordered reaches 300 million for 27 EU member states, all 300 million doses expected to be delivered in 2020 and 2021
Pfizer and BioNTech get EU authorisation for COVID-19 Vaccine
The EU authorisation is based on the totality of scientific evidence shared by the companies as part of the EMA’s rolling review…